^
Association details:
| Biomarker: | EGFR exon 21 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) + Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type
Published date:
09/14/2020
Excerpt:
RAM+ERL-treated pts with ex21 mut had similar treatment benefit as pts with ex19 mut...These results support RAM+ERL as a first-line therapy for both ex19 and ex21-positive met NSCLC.
Trial ID:
Source:
Title:
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Published date:
10/04/2019
Excerpt:
Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation...At the time of primary analysis, progression-free survival was significantly longer in the ramucirumab plus erlotinib group (19·4 months [95% CI 15·4-21·6])...Ramucirumab plus erlotinib demonstrated superior progression-free survival compared with placebo plus erlotinib in patients with untreated EGFR-mutated metastatic NSCLC.
DOI:
10.1016/S1470-2045(19)30634-5
Trial ID:
Source:
Title:
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)
Excerpt:
Eligible for first-line treatment with erlotinib based on documented evidence of tumor harboring an activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
Trial ID:
